My talk today was about new treatments of hepatocellular carcinoma, also about the new risk factors for the development of this tumour. I particularly am interested in some chronic liver diseases such as NAFLD, that is non-alcoholic steatohepatitis that is also related with NASH, non-alcoholic steatohepatitis, that it can progress to liver cirrhosis and also to hepatocellular carcinoma.

There are some very important risk factors, mainly obesity, metabolic syndrome and diabetes. As you know, there is a big increase in the prevalence of obesity and metabolic syndrome, especially in this country and in Mexico also we have a very high prevalence – 72% of our population are overweight or are obese and 12% of our population have diabetes mellitus. So those main risk factors are very important to the development of this condition, non-alcoholic steatohepatitis, and also develop the hepatocellular carcinoma.

So in the future we have to make some progress in new strategies and screening programmes to identify these kinds of patients and treat opportunely in order to avoid this development of the tumour.